MarketCap
Facebook
X
TelegramAnnual report 2024
added 01-03-2026
BioLineRx Ltd. Retained Earnings 2011-2026 | BLRX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings BioLineRx Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -278 M | -248 M | -223 M | -200 M | -175 M | -159 M | -140 M | -145 M | -119 M | -96.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -96.7 M | -278 M | -178 M |
Quarterly Retained Earnings BioLineRx Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -305 M | - | -295 M | - | -278 M | - | -261 M | - | -248 M | - | -234 M | - | -223 M | - | -211 M | - | -200 M | - | - | - | -175 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -175 M | -305 M | -243 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.1 B | $ 1.37 | -8.67 % | $ 350 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
-972 M | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
-311 M | $ 1.65 | 6.11 % | $ 92.9 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.43 | -2.69 % | $ 8.25 B |  Australia |
 |
Biogen
BIIB
|
19.3 B | $ 177.93 | -4.15 % | $ 25.9 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 B | $ 65.89 | -0.06 % | $ 8.81 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AstraZeneca PLC
AZN
|
5.3 B | $ 94.4 | 0.82 % | $ 96.9 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
-8.61 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
-575 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-362 M | - | -7.31 % | $ 87 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 214.55 | 2.77 % | $ 5 B |  Danmark |
 |
Codiak BioSciences
CDAK
|
-325 M | - | -55.98 % | $ 2.15 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
14.9 B | $ 55.84 | 0.13 % | $ 113 B | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
-1.4 B | - | - | $ 7.29 B | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M |  Canada |
 |
Caladrius Biosciences
CLBS
|
-548 M | - | -16.75 % | $ 25.8 M | USA |
 |
Clearside Biomedical
CLSD
|
-321 M | - | - | $ 25.3 M | USA |
 |
Chimerix
CMRX
|
-796 M | - | - | $ 756 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.02 B | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
-410 M | $ 106.88 | 4.6 % | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-166 M | $ 4.18 | -1.65 % | $ 9.1 B |  Israel |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 11.09 | 1.0 % | $ 730 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M | Israel |
 |
Coherus BioSciences
CHRS
|
-1.58 B | $ 1.69 | 2.12 % | $ 159 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
569 M | $ 28.99 | -1.39 % | $ 1.4 B | USA |
 |
Celldex Therapeutics
CLDX
|
-1.56 B | $ 25.71 | 0.16 % | $ 1.66 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
-2.52 B | - | - | $ 1.2 B | USA |
 |
Cellectis S.A.
CLLS
|
-506 M | $ 4.24 | -0.47 % | $ 116 M | France |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
|
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Brickell Biotech
BBI
|
-172 M | - | -5.38 % | $ 6.06 M | USA |